Longboard Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Longboard Pharmaceuticals

27/02/2024 22:47

* Longboard Pharmaceuticals Inc  LBPH.OQ   LBPH.O  is
expected
to show no change in quarterly revenue when it reports 
results on February 29 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Longboard
Pharmaceuticals Inc
is for a loss of 60 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Longboard
Pharmaceuticals Inc is $37.50​, above​ its last closing price
of $23.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.70       -0.70      -0.55     Beat    21.9
 Jun. 30 2023  -0.58       -0.60      -0.65     Missed  -9.1
 Mar. 31 2023  -0.57       -0.57      -0.56     Beat    2.5​
 Dec. 31 2022  -0.70       -0.69      -0.66     Beat    5
 ​​Sep.        -0.66       -0.64      -0.68     Missed  -6.9
 30 2022                                                
 Jun. 30 2022  -0.60       -0.57      -0.67     Missed  -17​
 Mar. 31 2022  -0.58       -0.55      -0.56     Missed  -1.3
 Dec. 31 2021  -0.42       -0.43      -0.52     Missed  -20.5
 This summary was machine generated February 27 at 22:47 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)